Can you discuss what monitoring and therapeutic end points—i.e., glucocorticoid sparing—were selected, and why, for the CAHtalyst trial? And what were the trial’s primary objectives?
Can you discuss what monitoring and therapeutic end points—i.e., glucocorticoid sparing—were selected, and why, for the CAHtalyst trial? And what were the trial’s primary objectives?
Associate Professor, Institute of Molecular Medicine Feinstein Institutes for Medical Research Emerita Professor, Pediatrics Donald and Barbara Zucker School of Medicine Hofstra/Northwell New Hyde Park, NY
